C 6872
Alternative Names: C-6872Latest Information Update: 18 Feb 2008
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 01 Nov 2005 Phase-I clinical trials in Atherosclerosis in USA (unspecified route)